Abstract
We read with great interest the recent paper written by Galeano-Valle et al. [1] and published in your journal. In this prospective observational study, the authors evaluated the presence of antiphospholipid (aPL) antibodies (anticardiolipin and anti-β2 glycoprotein I) in patients with COVID-19 pneumonia and venous thromboembolism (VTE). They chose not to assess lupus anticoagulant (LAC) due to false positivity in patients treated with heparin. This study found that the prevalence of aPL antibodies among COVID-19 patients with VTE was low, suggesting that aPL antibodies might not be involved in the pathogenesis of VTE in COVID-19 patients.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call